Entrada Shorted Ohio State Affiliate $20 Million Fees, Suit Says

The foundation managing Ohio State University’s intellectual property sued Entrada Therapeutics Inc., alleging it failed to pay more than $20 million in sublicensing fees from a Vertex Pharmaceuticals Inc. deal worth nearly $350 million.

Ohio State Innovation Foundation said Estrada sublicensed OSIF’s cell-penetrating peptides technology to Vertex without paying required fees under their 2018 agreement, according to a complaint filed Friday in the US District Court for the Southern District of Ohio. The technology helps therapeutic molecules cross cell membranes to treat genetic and neuromuscular disease.

• An independent royalty examiner found Entrada failed to disclose key documents and underpaid sublicensing ...